← Leaderboards
Aung Naing
University Of Tx Md Anderson Can Ctr
$1,978,906
Attributed
$1,978,906
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $657.1K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,978,906 · 2
By mechanism
R01$1,314,238 · 1
R21$664,668 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Kathrin Milbury$8,852,386
- Hoda J. Badr$6,550,695
- David Hui$7,552,634
- Goldy C George$776,699
- David S. Hong$3,694,798
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMonitorNational Cancer InstituteInstitutionTumorAntibodiesAngiogenesisAdvanced Malignant NeoplasmBiological MarkersBeta Chain Antigen T Cell ReceptorBiomarker ValidationBiopsyBlood SpecimenBreast SarcomaAffectCancer PatientCancer CenterBenefits And RisksCancer TherapyCancer Therapy Evaluation ProgramCaringCci-779Cell PhysiologyCancer Cell
Grant awards (4)
Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events$657,119
R01 · FY2025 · CA · contact PI
Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events$657,119
R01 · FY2024 · CA · contact PI
Phase I Study of IMC-A12 in Combination with Temsirolimus$332,334
R21 · FY2010 · CA · contact PI
Phase I Study of IMC-A12 in Combination with Temsirolimus$332,334
R21 · FY2009 · CA · contact PI